FDA Approves DIAZEPAM — Hikma Pharmaceuticals USA Inc.

# FDA Approves Hikma Pharmaceuticals' Intramuscular Diazepam Formulation Hikma Pharmaceuticals USA Inc. has received FDA approval for an intramuscular formulation of diazepam, expanding its portfolio in the benzodiazepine market and positioning the company to compete in the acute anxiety and seizure management segments. The approval of the injectable formulation could enhance Hikma's reach in hospital and emergency care settings where rapid-acting sedatives are critical, potentially strengthening its presence in institutional healthcare markets.